Drug intelligence / Profile preview

LPMX-3

Development stage: Preclinical
Lead developer: Lipomedix

Overview

LPMX-3 is an investigational drug developed by Lipomedix Pharmaceuticals for the treatment of solid tumors. It is currently in preclinical development. Specific details regarding its mechanism of action, molecular structure, or formulation have not been disclosed publicly as of June 2025. The drug is part of Lipomedix's pipeline focused on oncology therapeutics[1].

Beyond the preview

Go deeper on LPMX-3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LPMX-3.

Explore the full profile